India, July 1 -- July is here, and the FDA is set to announce decisions on therapies for conditions ranging from breast cancer and IgA nephropathy to multiple myeloma, ADHD, and wet AMD.
Before turning our attention to the key FDA decisions expected in July, here are some of the newsworthy regulatory headlines of June.
For the first time in more than two decades, the FDA approved a new active ingredient for over-the-counter (OTC) sunscreens. On June 9, 2026, the U. regulator added Bemotrizinol to the list of permitted sunscreen active ingredients, marking a significant milestone in its efforts to advance sunscreen innovation. Bemotrizinol is the first new sunscreen active ingredient added to the over-the-counter (OTC) sunscreen monograph ...